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Impact of Antiretroviral Regimens on Cerebrospinal 
Fluid Viral Escape in a Prospective Multicohort 
Study of Antiretroviral Therapy-Experienced Human 
Immunodeficiency Virus-1–Infected Adults in the 
United States
Shibani S. Mukerji,1,2 Vikas Misra,1 David R. Lorenz,1 Hajime Uno,1 Susan Morgello,3 Donald Franklin,4 Ronald J. Ellis,4 Scott Letendre,4 and Dana Gabuzda1
1Dana-Farber Cancer Institute, and 2Massachusetts General Hospital, Boston; 3Icahn School of Medicine at Mount Sinai, New York, New York; and 4University of California–San Diego School of 
Medicine
Background. Cerebrospinal fluid (CSF) viral escape occurs in 4%–20% of human immunodeficiency virus (HIV)–infected 
adults, yet the impact of antiretroviral therapy (ART) on CSF escape is unclear.
Methods. A prospective study of 1063 participants with baseline plasma viral load (VL) ≤400 copies/mL between 2005 and 
2016. The odds ratio (OR) for ART regimens (protease inhibitor with nucleoside reverse transcriptase inhibitor [PI + NRTI] vs other 
ART) and CSF escape was estimated using mixed-effects models.
Results. Baseline mean age was 46 years, median plasma VL, and CD4 count were 50 copies/mL, and 424 cells/μL, respectively. 
During median follow-up of 4.4 years, CSF escape occurred in 77 participants (7.2%). PI + NRTI use was an independent predic-
tor of CSF escape (OR, 3.1; 95% confidence interval, 1.8–5.0) in adjusted analyses and models restricted to plasma VL ≤50 copies/
mL (P < .001). Regimens that contained atazanavir (ATV) were a stronger predictor of CSF viral escape than non-ATV PI + NRTI 
regimens. Plasma and CSF M184V/I combined with thymidine-analog mutations were more frequent in CSF escape vs no escape 
(23% vs 2.3%). Genotypic susceptibility score–adjusted central nervous system (CNS) penetration-effectiveness (CPE) values were 
calculated for CSF escape with M184V/I mutations (n = 34). Adjusted CPE values were low (<5) for CSF in 27 (79%), indicating 
suboptimal CNS drug availability.
Conclusions. PI + NRTI regimens are independent predictors of CSF escape in HIV-infected adults. Reduced CNS ART bioavail-
ability may predispose to CSF escape in patients with M184V/I mutations.
Keywords. CSF viral escape; HIV-1; protease inhibitor; drug resistance mutations; antiretroviral therapy.
Contemporary antiretroviral therapy (ART) is effective at reduc-
ing plasma and cerebrospinal fluid (CSF) human immunode-
ficiency virus type 1 (HIV-1) RNA viral loads (VL) to below 
detectable levels and preventing severe forms of HIV-associated 
cognitive impairment [1–4]. In some individuals, HIV RNA can 
be detected in CSF despite plasma ART suppression, an event 
termed CSF viral escape [2, 5]. Neurologically symptomatic CSF 
escape frequently occurs in the setting of drug resistance mutations 
(DRMs) [5–7], while asymptomatic CSF escape has been detected 
when lumbar punctures are obtained for research [8, 9]. 
The long-term implications of CSF escape remain unclear.
CSF escape occurs in approximately 4%–20% of ART-
experienced HIV-infected adults worldwide [10]. Low nadir 
CD4+ T-cell count, duration of HIV infection, and low-level vire-
mia are risk factors for CSF escape [6, 7]. ART penetration into 
the central nervous system (CNS) varies by medication, with low-
er-penetrance ART regimens associated with higher CSF HIV-1 
RNA [11, 12]. In contrast to other ART classes, protease inhibitors 
(PI), particularly atazanavir (ATV), do not consistently achieve in 
vitro 50% inhibitory concentrations (IC50) for wild-type HIV-1 
in CSF, raising the possibility that CNS concentrations of certain 
PI regimens may be subtherapeutic in some individuals [13, 14]. 
The relationship between ART drug classes and likelihood of CSF 
escape has not been investigated in longitudinal studies, in part, 
due to low prevalence of CSF escape and need for large-scale stud-
ies to evaluate risk posed by specific ART regimens [15].
Our aim in this study was to determine the impact of ART 
on the probability of CSF escape in a prospective study of 1063 
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ART-experienced HIV-infected participants enrolled in US-based, 
multisite cohorts from 2005–2016. Given the known association of 
CSF escape with HIV-1 resistance mutations, the frequency of DRMs 
in reverse transcriptase (RT) and protease genes from a merged 
cohort of participants and published studies was also examined.
METHODS
Participants
This prospective cohort included data from the National 
NeuroAIDS Tissue Consortium (NNTC), CNS HIV Anti-
Retroviral Therapy Effects Research (CHARTER), and HIV 
Neurobehavioral Research Center (HNRC) between January 
2005 and September 2016. Criteria and data collection for 
individual cohorts have been described [16–18]. Eligible par-
ticipants were age ≥18 years with at least 1 paired plasma and 
CSF VL measurement (Figure  1). Participants were followed 
from the first date after 2005 with plasma VL <400 copies/mL 
until the participant’s final recorded visit or second consecutive 
visit with plasma VL ≥1000 copies/mL, considered to represent 
virologic failure. Subsequent analyses were right censored to the 
last paired plasma and CSF VL in follow-up. CSF escape was 
defined as paired CSF VL > plasma VL (98% within 24 hours). 
If plasma VL was undetectable by clinical diagnostic assay (85% 
with lower limit of quantification of 50 copies/mL), CSF VL 
≥51 copies/mL was denoted as CSF escape. The institutional 
review board at the NNTC, CHARTER, and HNRC clinical 
sites approved the research, and participants signed a written 
statement of informed consent.
Calculation of DRMs and CNS Penetration Values
In a combined dataset of cohort participants with available 
genotypes (n = 50) and genotypes from published CSF escape 
cases (n = 49; [5]), frequencies of CSF and plasma mutations 
in RT and protease genes were analyzed. Frequencies of indi-
vidual HIV-1 mutations were calculated for participants with 
and without CSF escape. The effectiveness of CNS ART pen-
etration was estimated for each regimen using the CNS pene-
tration effectiveness (CPE) value [19]. Genotypic susceptibility 
scores (GSS) were calculated using CSF or plasma genotypes 
and assigning a score of 0 (resistant), 0.5 (intermediate resis-
tance), or 1 (susceptible) to each drug [20]. GSS-adjusted CPE 
scores were calculated by multiplying the CPE value by the GSS 
for each ART drug and summing scores.
Statistical Analyses
Given repeated plasma and CSF VL measures within the same 
individual, the probability of CSF escape was estimated using 
generalized mixed-effects models for repeated binary outcome 
in PROC GLIMMIX (SAS 9.4 Institute, Cary, North Carolina). 
The primary covariate of interest was PI with 2 nucleoside 
reverse transcriptase inhibitors (PI + NRTI) vs other ART regi-
mens. Regimens that combined a PI with a non-NRTI (NNRTI) 
and NRTI were classified as other ART. Adjusted continuous 
Figure 1. Selection of the human immunodeficiency virus-infected (HIV+) study cohort, 2005–2016. The sequential application of inclusion and exclusion criteria to define 
the study population is shown. If cerebrospinal fluid escape was not present during the observation period, the participant was defined as a control. If participants were 
enrolled in both studies, data from the CHARTER-HNRC cohort was used to prevent data duplication. Abbreviations: CHTR-HNRC, CHARTER-HIV Neurobehavioral Research 
Center; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; N, number of participants; NNTC, National NeuroAIDS Tissue Consortium; VL, viral load.
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covariates included duration of HIV infection based on self-re-
port, nadir CD4+ T-cell count, age at study visit, and number of 
lumbar punctures to adjust for sampling bias; modeled binary 
covariates included plasma VL (suppressed [≤50 copies/mL] 
vs nonsuppressed) and cohort indicator (NNTC vs CHARTER 
and HNRC combined). Of 11 622 total person-visits, 300 vis-
its (2.6%) were among participants on monotherapy or non-
standard drug regimens that did not include at least 2 NRTIs 
in combination with a third active ART drug from another 
class. Monotherapy is associated with virologic failure and 
development of DRMs [21]; therefore, we excluded monother-
apy or nonstandard regimens from mixed-effects models as 
they may falsely overestimate probability of CSF viral escape 
(see Supplementary Methods).
RESULTS
A total of 1063 participants met eligibility criteria, of which 
77 (7.2%) developed CSF escape during median follow-up of 
4.4  years. Participants were 81.6% men, 48.4% white, 31.2% 
black, ranged in age from 19 to 79 years (mean = 46.2, standard 
Table 1. Baseline Cohort Characteristics of Cerebrospinal Fluid Viral Escape in National NeuroAIDS Tissue Consortium and CHARTER-HRNC, 2005–2016
Characteristic
Cerebrospinal Fluid Escape 
(n = 77)
Total Cohort 
(n = 1063)
Years of observation, median (IQR) 5.82 (2.92, 8.88) 4.39 (1.59, 7.65)
Baseline age (years), mean (SD) 45.79 (8.16) 46.18 (8.87)
Male gender, n (%) 64 (83.1) 867 (81.6)
Race, n (%)
 White 45 (58.4) 514 (48.4)
 Black 21 (27.3) 332 (31.2)
 Other 11 (14.3) 217 (20.4)
Years of education (>12 years), n (%) 44 (57.1) 575 (54.1)
Baseline year, n (%)
 2005–2008 66 (85.7) 896 (84.3)
 2009–2012 10 (13.0) 148 (13.9)
 2013–2016 1 (1.3) 19 (1.8)
Baseline HIV disease characteristics
 Duration of HIV infection (>10 years), n (%) 61 (79.2) 633 (60.9)
 Plasma viral load (copies/mL), median (IQR) 50 (50, 109) 50 (50, 50)
 Nadir CD4+ T-cell count (cells/µL), median (IQR) 50 (5, 183) 89 (14, 200)
 CD4+ T-cell count (cells/µL), median (IQR) 364 (187, 539) 424 (253, 626)
 CD4/CD8 ratio, median (IQR) 0.36 (0.20, 0.67) 0.49 (0.28, 0.75)
Baseline antiretroviral therapy regimen, n (%)
 PI + NRTIs 50 (64.9) 514 (48.4)
 Other ART
  Integrase inhibitor + NRTIs 2 (2.6) 60 (5.6)
  NNRTI + NRTIs 10 (13.0) 289 (27.2)
  PI + NNRTI + NRTIs 4 (5.2) 63 (5.9)
 Monotherapy/nonstandard therapya 2 (2.6) 37 (3.5)
 Specific drugs in regimen
  Atazanavir 24 (31.2) 241 (22.7)
  Lopinavir 10 (13.0) 185 (17.4)
  Darunavir 8 (10.4) 66 (6.2)
  Efavirenz 10 (13.0) 255 (24.0)
  Abacavir 15 (19.5) 233 (21.9)
  Central nervous system penetration-effectiveness value (mean (SD)) 7.8 (2.2) 8.0 (2.0)
Neurological coinfections, n (%)
 Number of patients with coinfectionsb 26 (33.8) 270 (25.4)
  Neurosyphilis, n (%) 9 (11.7) 114 (10.7)
  Herpesc 10 (13.0) 126 (11.9)
  Progressive multifocal leukoencephalopathy 5 (6.5) 27 (2.5)
  Cryptococcus and/or Toxoplasmosis 3 (3.9) 40 (3.8)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse 
transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation.
aNonstandard therapy: regimen inconsistent with 2 NRTIs in combination with a third active antiretroviral therapy drug from another class.
bCentral nervous system coinfections were counted if infection occurred within 2 years prior or 1 year after cerebrospinal fluid (CSF) escape or last CSF visit. Multiple coinfections were 
reported in some patients. 
cIncludes varicella zoster virus encephalitis or vasculopathy and/or cytomegalovirus encephalitis (Supplementary Table 1).
 • CID 2018:67 (15 October) • 1185Impact of ART on CSF Escape in HIV
deviation = 8.87 years), and the majority entered observation 
during 2005–2008 (Table 1). At baseline, the majority of par-
ticipants with CSF escape had been HIV infected for more than 
10 years (79%) and had low median nadir CD4+ T-cell counts 
(50 cells/µL); 65% reported being on a PI-based regimen.
CSF Escape
Among 77 participants with CSF escape, median plasma VL 
was 50 copies/mL, CD4+ T-cell count was 394 cells/µL, and the 
CD4-to-CD8 ratio was 0.44 at first instance of escape (Table 2). 
Symptomatic neurocognitive deficits were more frequent in 
participants with CSF escape (35% vs 20%), while 40% were 
neurocognitively unimpaired. The distribution of ART regi-
mens is shown in Table 2; 66% were on a PI-based regimen with 
ATV, darunavir, and lopinavir as the most frequent PIs, 22% 
were on a NNRTI-based regimen, and 3 were on an integrase 
inhibitor (raltegravir) at the time of first escape. The mean CPE 
value did not differ between groups (P = .3). Sixty-five partic-
ipants (84%) had been on other ART regimens before the first 
CSF escape. Twenty-five of 30 participants with available adher-
ence data and CSF escape (83%) reported adherence to ART, 
while 5 (17%) were nonadherent within 1 year of their first CSF 
escape. These estimates were comparable to those for partici-
pants without CSF escape within 1 year of their last paired CSF 
visit (adherent, 310 participants [90%]; nonadherent, 33 par-
ticipants [9.6%]). The proportion of missing adherence data 
was similar for participants with and without CSF escape (61% 
vs 65%), respectively. CSF escape was observed at 135 visits, 
with 26 participants (34% of those with escape; Supplementary 
Table 2) demonstrating multiple instances of higher HIV RNA 
Table 2. Factors Associated With First Cerebrospinal Fluid (CSF) Viral Escape or Last Paired CSF-Plasma Viral Load Visit
Characteristic
CSF Viral Escape 
(n = 77)
No CSF Viral Escape 
(n = 986) P  Value
HIV disease characteristics, median (IQR)
 Plasma viral load (copies/mL) 50 (40, 115.50) 50 (40, 50) .24
 Nadir CD4+ T-cell count (cells/µL) 46 (4, 180) 94 (15, 203) <.01
 CD4+ T-cell count (cells/µL) 394 (220, 578) 497.5 (311, 715) <.01
 CD4/CD8 ratio 0.44 (0.25, 0.71) 0.62 (0.36, 0.91) .01
CSF studies, median (IQR)
 Viral load (copies/mL) 300 (141, 1780) 50 (40, 50) <.01
 White blood cell count (cells/µL) 5 (2, 13) 2 (1, 3) <.01
 Protein (mg/dL) 45 (36, 57) 38 (29, 49) <.01
 No. CSF viral load analyses/subject, median (IQR)a 5 (3, 9) 4 (2, 6) <.01
 Neurocognitive status,b n (%) .01
 Symptomatic neurocognitive impairment 27 (35.1) 198 (20.4) …
  HIV-associated dementia 7 (9.1) 52 (5.4) …
  Mild neurocognitive disorder 13 (17.1) 99 (10.2) …
  Neuropsychiatric impairment–other 7 (9.1) 47 (4.8) …
 Asymptomatic neurocognitive impairment 17 (22.1) 297 (30.6) …
 Neurocognitively unimpaired 33 (42.9) 475 (49.0) …
ART Regimens, n (%)
 PI + NRTIs 51 (66.2) 464 (47.1) <.01
 Other ART 20 (26.0) 491 (49.8) …
  Integrase inhibitor + NRTIs 3 (3.9) 153 (15.5) …
  NNRTI + NRTIs 13 (16.9) 287 (29.1) …
  PI + NNRTI + NRTIs 4 (5.2) 51 (5.2) …
 Monotherapy/nonstandard therapyc 4 (5.2) 17 (1.7) …
 Specific drugs in regimen
  Atazanavir 27 (35.1) 226 (22.9) .02
  Lopinavir 9 (11.7) 135 (13.7) .75
  Darunavir 10 (13.0) 143 (14.5) .84
  Efavirenz 13 (16.9) 224 (22.7) .3
  Abacavir 16 (20.8) 221 (22.4) .85
  Central nervous system penetration-effectiveness value (mean (SD)) 7.7 (2.1) 7.9 (1.8) .3
Bold indicates significant after Bonferroni correction (P ≤ .01).
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, 
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standard deviation. 
aNumber of CSF analyses performed during follow-up. 
bNearest available neurocognitive status (n = 1047; 98.5% cohort). Two-way analysis of variance comparing symptomatic neurocognitive impairment, asymptomatic neurocognitive impair-
ment, and neurocognitively unimpaired.
cNonstandard therapy; regimen inconsistent with 2 NRTIs in combination with a third active ART drug from another class.
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levels in CSF compared to plasma. Participants with repeated 
CSF escape were younger (P = .01) and more likely to be on a 
PI-containing regimen (88% vs 55%, P = .03) than those with 
only 1 escape episode (Supplementary Table 3).
Analysis of visits with paired CSF and plasma VL showed 
a 3.7-fold greater odds of CSF escape in participants on PI + 
NRTI regimens compared to other ART regimens in univariate 
analysis (Table 3). In multivariable mixed-effects models, there 
was a 3.9-fold increased odds of CSF escape (95% confidence 
interval [CI], 2.5–6.2) on PI + NRTI regimens after account-
ing for years of HIV infection; the predicted mean probabil-
ity of CSF escape over 20 years of HIV infection is shown in 
Figure  2A. In models adjusted for nadir CD4+ T-cell count, 
years of HIV infection, age, plasma viral suppression, number 
of CSF analyses, and cohort, the association between PI use and 
CSF escape remained significant, with an estimated 3.1-fold 
odds of CSF escape on PI-based therapy (95% CI, 1.9–5.1) at 
15 years of HIV infection (Table 3). Lower nadir CD4+ T-cell 
count (P =  .03), younger age (P <  .0001), and plasma VL >50 
copies/mL (P  =  .01) were additional independent risk factors 
associated with CSF escape. Participants in the NNTC cohort 
were more likely to have CSF escape than those in CHARTER–
HNRC cohorts, which may reflect more advanced stages of HIV 
disease in the NNTC cohort. Cohort was not a factor when 
the dataset was restricted to visits with suppressed plasma VL 
(Supplementary Table 4) [16]. The number of CSF analyses was 
also not associated with increased odds of CSF escape (P = .7).
The association between PI + NRTI regimens and CSF escape 
remained significant in sensitivity analyses limited to visits 
with plasma VL ≤50 copies/mL (odds ratio [OR], 3.8 [2.0–7.6]; 
Supplementary Table 4). Stability of results was further confirmed 
in multivariable models limited to the first CSF escape event or 
last paired CSF and plasma VL (PI + NRTI vs other ART; OR, 
2.2; 95% CI, 1.2–4.0) and in multivariable models using months 
in follow-up as a proxy for time (PI + NRTI vs other ART; OR, 
3.1; 95% CI, 2.0–4.8); months in follow-up was not significantly 
associated with escape (P = .84). Adjusted mixed-models were fit 
using 10 imputed datasets, and pooled estimates demonstrated 
similar associations between PI + NRTI regimens vs other ART 
(3.1, OR; 95% CI, 2.6–3.6; data not shown) and CSF escape, sug-
gesting that missingness is unlikely to account for the relation-
ship between PI-based regimens and CSF escape.
ATV and CSF Escape
ATV was the most commonly reported PI. ATV achieves lower 
CSF concentrations than other PI drugs and does not consist-
ently achieve the IC50 in CSF [13]. After adjusting for dura-
tion of HIV infection in mixed-effects models, ATV-containing 
and non–ATV-containing regimens had a 3.9-fold (95% CI, 
2.4–6.3) and 3.4-fold (95% CI, 2.1–5.6) increased odds for CSF 
escape compared to other ART regimens, respectively (Table 3). 
The probability of CSF escape was not significantly different 
between ATV-containing compared to non–ATV-containing 
regimens and CSF escape, suggesting that while regimens with 
ATV pose an increased likelihood of CSF escape, it is not the 
only PI-based regimen associated with CSF escape (Figure 2B). 
In fully adjusted models, ATV-containing regimens (OR, 3.1; 
95% CI, 1.9–5.3) remained a stronger independent predictor for 
Figure 2. Protease inhibitor use is associated with higher probability of cerebrospinal fluid (CSF) escape in human immunodeficiency virus (HIV)–infected adults on combi-
nation antiretroviral therapy (ART). A, Estimated mean probability of CSF escape according to protease inhibitor with nucleoside reverse transcriptase inhibitors (PI+NRTI) use 
vs other ART regimens over the estimated duration of HIV infection. B, PI use is associated with increased probability of CSF escape when compared to other ART multidrug 
regimens (P < .001). Atazanavir-containing regimens account for a portion of the increased probability of CSF escape among PI-containing regimens compared to other ART 
regimens (P < .0001). CSF escape is independently associated with longer duration of HIV infection in both models (P < .001). Abbreviations: ART, antiretroviral therapy; ATV, 
atazanavir; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. 
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CSF escape than nadir CD4+ T-cell count (OR, 1.3; 95% CI, 
1.0–1.6) or years of HIV infection (OR, 1.7; 95% CI, 1.4–2.0).
HIV-1 Genotyping and DRMs
DRMs are associated with worse clinical outcomes [22] and 
reported in neurologically symptomatic CSF escape [5, 6]. We 
hypothesized that ART regimens with incomplete viral suppression 
in the CNS could lead to development of DRMs. Among partici-
pants with CSF escape using the combined dataset of cohort par-
ticipants and published CSF cases, M184V or M184I (M184V/I) 
mutations were detected in CSF and plasma in 61% (34/56) and 
30% (16/55) of samples, respectively, while M184V/I mutations in 
CSF and plasma were detected in only 7% (3/43) of samples from 
participants without escape (Supplementary Table  5). Given the 
high frequency of M184V/I detected in all samples (28%, 56/197), 
these mutations were combined with thymidine-analog mutations 
(TAMs; ie, M41L, L210W, T215Y, D67N, K70R, T215F, K219Q/E) 
for analysis. In 23% (13/56) of CSF escape cases, M184V/I mutation 
was detected with at least 1 TAM in CSF compared to 15% (8/55) 
in plasma, potentially lowering the threshold for accumulation 
of other mutations that lead to NRTI cross resistance in the CNS 
(Figure 3D) [23, 24]. Major but not accessory resistance mutations 
were more frequent in CSF among those with CSF escape compared 
to participants without CSF escape (Figure 3A and 3B).
M184V/I Mutations and CPE Values
M184V/I mutations reduce HIV-1 viral fitness [25], can delay 
emergence of TAMs [23], and are frequently present in ART-
experienced individuals [6, 26]. While ART drug regimens with 
higher CPE values are associated with lower CSF VL [11, 27], CPE 
values do not reflect resistance mutations. We therefore identified 
ART-experienced participants with CSF escape and M184V/I 
mutations on genotypic resistance tests in CSF and/or plasma from 
published studies (n = 34 [5]) and calculated CPE values based on 
reported ART drug regimens at CSF escape. GSS was calculated 
by assigning a value to each ART drug, and the composite score 
accounting for viral resistance and CNS penetration was calculated 
(GSS-adjusted CPE), as described [20]. Among 34 HIV-infected 
participants with M184V/I, the median CPE value was 7 (inter-
quartile range [IQR], 7–8), consistent with median CPE values in 
published studies [20, 28], while GSS-adjusted CPE values were 
6 (IQR 4–7) in plasma and 3.5 (IQR 3–4) in CSF (Figure  3C). 
Although there are no clinically recommended CPE cutoffs, reg-
imens with CPE values of <5 are generally considered suboptimal 
Table 3. Predictors Associated With Cerebrospinal Fluid Viral Escape in Mixed-Effects Logistic Regression Models
Predictor
PIs vs Other ART Regimens
Atazanavir-Containing, Non–Atazanavir-
Containing PI vs Other ART Regimens
Unadjusted Model 
(n = 5732)
Time Adjusted Model 
(n = 5663)
Covariate Adjusted 
Model (n = 5663)
Time Adjusted Model 
(n = 5663)
Covariate Adjusted 
Model (n = 5663)
OR  
(95% CI) P  Value
OR  
(95% CI) P Value
OR  
(95% CI) P  Value
OR  
(95% CI) P  Value
OR  
(95% CI) P  Value
ART regimen
 PI + NRTIs 3.7 (2.4–5.8) <.01 3.9 (2.5–6.2) <.01 3.1 (1.9–5.1) <.01 … … … …
 Other ART 1.0 (Ref.) … 1.0 (Ref.) … 1.0 (Ref.) … … … … …
ART regimen
 Atazanavir-containing ... ... ... ... ... ... 3.9 (2.4–6.3) <.01 3.1 (1.9–5.3) <.001
 Non-atazanavir-containing PI ... ... ... ... ... ... 3.4 (2.1–5.6) <.01 2.7 (1.6–4.5) <.01
 Other ART ... ... ... ... ... ... 1.0 (Ref.) ... 1.0 (Ref.) ...
Estimated years of human 
immunodeficiency virus infectiona
... ... 1.5 (1.3–1.7) <.01 1.7 (1.4–2.0) <.01 1.5 (1.3–1.7) <.01 1.7 (1.4–2.0) <.01
Nadir CD4+ T-cell countb ... ... ... ... 1.2 (1.0–1.5) .03 ... ... 1.3 (1.0–1.6) .02
Age at study visitc ... ... ... ... 0.9 (0.9–1.0) <.01 ... ... 0.9 (0.9–1.0) <.01
Plasma viral load
 Nonsuppressed (>50 copies/mL) ... ... ... ... 1.7 (1.2–2.6) .01 ... ... 1.7 (1.2–2.6) <.01
 Suppressed (≤50 copies/mL) ... ... ... ... 1.0 (Ref.) ... ... ... 1.0 (Ref.) ...
Number of lumbar punctures ... ... ... ... 1.0 (1.0-1.0) .77 ... ... 1.0 (1.0-1.0) .67
Cohort indicator
  National NeuroAIDS Tissue 
Consortium
... ... ... ... 1.7 (1.1–2.7) .02 ... ... 1.7 (1.1–2.7) .02
  CHARTER-HIV Neurobehavioral 
Research Center
... ... ... ... 1.0 (Ref.) ... ... ... 1.0 (Ref.) ...
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; Ref., reference. 
aOR per 5 years of estimated years of human immunodeficiency virus infection.
bOR per 100 cell decrement in nadir CD4+ T-cell count. 
cOR per year. For mixed models, all values must be present to be modeled. Models were fit using Proc GLIMMIX for logistic regression for repeated measures with cerebrospinal fluid 
escape as the dependent variable and predictors as fixed effects. Adjusted models were analyzed with random intercept and time.
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CNS penetration of ART [11, 20, 27, 29]. In participants with CSF 
escape and M184V/I mutations, GSS-adjusted CPE values were <5 
for CSF and plasma in 27 (79%) and 13 (38%) of 34 participants, 
respectively, indicating that the majority of those with M184V/I 
mutations and CSF escape have a low estimated ART penetration 
in the CNS (Supplementary Table 6).
DISCUSSION
In this prospective multisite study of 1063 ART-experienced HIV-
infected participants during 2005–2016, PI regimens were associ-
ated with 3-fold higher odds of CSF escape compared to other ART 
regimens in adjusted mixed-effects models. Additionally, individuals 
on ATV had increased likelihood of CSF escape compared to non–
PI-based regimens. Lower nadir CD4+ T-cell count and longer dura-
tion of HIV infection remained associated with CSF escape despite 
plasma suppression, which is consistent with previous studies [6, 10, 
30]. To our knowledge, these data represent the largest longitudinal 
analyses of CSF escape predictors among HIV-infected adults on 
ART. These analyses also show that CSF escape cases with M184V/I 
are likely to harbor variants with major DRMs that confer resistance 
to at least 1 ART drug. These findings highlight ART drug classes 
and/or individual drugs as important predictors of CSF escape, poten-
tially through mechanisms that involve suboptimal CNS penetration, 
incomplete control of viral replication, and DRM accumulation.
ART regimens have highly variable penetration in tissue 
compartments including the CNS, leading to lower drug con-
centrations compared to peripheral blood [14, 19, 31, 32]. In 
nonhuman primate models, low viral RNA levels were detected 
in brain despite suppressive ART and were correlated with 
reduced drug concentrations in non-CNS tissues compared 
to peripheral blood mononuclear cells [31, 32]. PIs penetrate 
the CNS less effectively than other ART classes, as evidenced 
by CSF concentrations <1% of those in plasma [11, 13, 33]. In 
13 boosted, protease-inhibitor monotherapy, randomized, con-
trolled, clinical trials, there were 6 cases of detectable CSF VL, 
all in the boosted-PI monotherapy arm [15]. Our mixed-effects 
analyses excluded visits while on monotherapy and showed that 
combination PI-based regimens still pose a 3-fold higher odds 
of CSF escape compared to other ART regimens. The associa-
tion with PI-based ART regimens remained significant when 
only the first episode of detectable CSF VL was analyzed, was 
stronger when repeated events were considered, and suggests 
PI-based therapy may not adequately control virus in the CNS 
despite achieving plasma suppression [31].
The CPE method remains a topic of controversy, with some 
studies suggesting improved neurocognitive scores or lower 
CSF HIV-1 RNA with higher CPE values [11, 27, 28, 34], while 
others show no association or worse outcomes [35, 36]. When 
an adjustment was factored into CPE values to account for drug 
Figure 3. Frequency of major resistance mutations and adjusted central nervous system penetration-effectiveness (CPE) values in plasma and cerebrospinal fluid (CSF) 
among participants with CSF escape. The frequencies of resistance mutations in CSF and plasma in reverse transcriptase and protease genes are shown by human immuno-
deficiency virus (HIV)–infected participants with CSF escape (red) and no CSF escape (blue) during the study period. For simplicity, M184V/I mutations were combined with 
thymidine analog mutations (TAMs). Major resistance mutations (A), but not accessory resistance mutations (B), were more frequent in those with CSF escape compared to 
those without CSF escape. HIV-infected adults with CSF escape and M184V/I mutations on genotypic resistance tests in CSF and/or plasma were identified from published 
studies (n = 34). Median CPE values were 7 (interquartile range [IQR], 7–8), but genotypic susceptibility score–adjusted CPE values were 6 (IQR, 4–7) in plasma and 3.5 (IQR, 
3–4) in CSF (C). Schematic diagram showing the predicted resistance to nucleoside reverse transcriptase inhibitor with M184V/I mutations [24]. Abbreviations: CNS, central 
nervous system; CPE, central nervous system penetration effectiveness; CSF, cerebrospinal fluid; GSS, genotypic susceptibility scores; HIV, human immunodeficiency virus; 
TAM, thymidine analog mutation.
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resistance, Peluso et al found that the adjusted CPE value was 
thought to be a more accurate reflection of ART penetration 
in CSF escape [6]. A  similar strategy was used to determine 
impact of ART regimens on neurocognitive impairment and 
showed improved correlations with cognitive scores compared 
to unadjusted CPE values [20]. In our study, CPE values were 
similar between those with and without CSF escape, suggesting 
that unadjusted values alone may not discriminate those at risk 
for CSF escape. However, when resistance mutations were fac-
tored into CPE values among participants with common NRTI 
M184V/I mutations, median adjusted CPE scores in CSF were 
low, suggesting that accumulation of resistance mutations in 
the CNS may lead to ineffective viral control despite regimens 
with high unadjusted CPE values. Participants in our study 
cohort had historical immunosuppression, as evidenced by low 
median nadir CD4+ T-cell counts, and the majority had long 
duration of HIV infection. We hypothesize that a sequential 
process rather than a single driver is necessary for CSF escape, 
with several factors that include accumulated CNS DRMs and 
insufficient ART penetration leading to periodic CNS viral 
replication.
This study has several limitations, including potential selec-
tion bias for participants enrolled in research studies. While 
the estimated prevalence of CSF escape is consistent with those 
listed in other publications of CSF escape [5, 7–9], some par-
ticipants were enrolled in neurological substudies that may be 
subject to referral bias and therefore may overestimate prev-
alence of CSF escape compared to the general HIV-infected 
population. Additionally, choice of ART regimen is not random 
in ART-experienced patients; thus, potential channeling biases 
cannot be fully accounted for in these analyses. The majority of 
CSF escape cases were exposed to prior ART regimens. While 
reasons for ART switch were not available, plasma VL, duration 
of HIV infection, and nadir CD4 count were adjusted for in 
analyses, and the follow-up period was restricted to visits with 
plasma VL <1000 copies/mL on consecutive visits to reduce 
biases that result from virological failure. ART adherence is a 
critical factor in maintaining durable viral suppression [37] and 
could not be fully assessed due to missing data at the time of CSF 
escape. However, subanalyses of visits with suppressed plasma 
VL as a proxy for ART suppression showed that PI use remained 
an independent predictor of CSF escape. Additional limitations 
include the limited number of participants on integrase inhibi-
tors at the time of CSF escape. Last, only a subset of participants 
had available HIV-1 genotypes, and samples were not available 
to perform resistance testing at CSF escape episodes.
The search for a functional cure is a top priority for HIV 
research [38]. Latently infected cells that harbor integrated HIV 
DNA persist within the CNS, [39] are not cleared with sup-
pressive ART and represent a potential source of viral rebound. 
Analyses in this study suggest that individuals on PI-based 
regimens are at elevated risk for CSF escape, and that risk may 
extend to individuals with historic M184V/I mutations and 
CSF accumulation of major DRMs. Understanding viral and 
host factors associated with incomplete suppression of CSF 
HIV-1 RNA during ART is an important step toward identify-
ing patients with CNS reservoirs and has clinical implications, 
particularly in those with neurological symptoms, regarding 
optimal ART regimens for ART-experienced patients.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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